Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

Journal of Urology

Volumn 158, Issue 4, 1997, Pages 1441-1445

  Patel, Anup ^a   Dorey, Frederick ^a   Franklin, John ^a   DeKernion, Jean B ^a  

^a NONE

Author keywords

Linear models; Prostate; Prostate specific antigen; Prostatectomy; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL MODEL;

EID: 0030815150     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64238-1     Document Type: Article

References (21)

1. Walsh, P., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., 152: 1831, 1994.
2. Paulson, D. F., Moul, J. W. and Walther, P. J.: Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J. Urol., 144: 1180, 1990.
3. Stein, A., deKernion, J. B., Smith, R. B., Dorey, F. and Patel, H.: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J. Urol., 147: 942, 1992.
4. Zincke, H., Blute, M. L., Fallen, M. J. and Farrow, G. M.: Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J. Urol., 146: 1053, 1991.
5. Goldrath, D. E. and Messing, E. M.: Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J. Urol., 142: 1082, 1989.
6. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
7. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., 152: 1821, 1994.
8. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. Urol. Clin. N. Amer., 20: 713, 1993.
9. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 152: 1850, 1994.
10. Catalona, W. J. and Smith, D. S.: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
11. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
12. Kupelian, P., Katcher, J. and Levin, H.: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology, 48: 249, 1996.
13. Partin, A. W., Pearson, J. D. and Landis, P. K.: Evaluation of prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology, 43: 649, 1994.
14. Partin, A. W., Piantadosi, S. and Sanda, M. G.: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995.
15. Danella, J., Steckl, J. and Dorey, F.: Detectable prostate specific antigen levels following radical prostatectomy: relationship of doubling time to clinical outcome. J. Urol., part 2, 149: 447A, abstract 938, 1993.
16. Fowler, J. E., Pandey, P. and Braswell, N. T.: Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. Surgery, 116: 302, 1994.
17. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
18. Schellhammer, P. F.: Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology, 47: 622, 1996.
19. Crawford, E. D., Eisenberger, M. A. and McLeod, D. G.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med., 321: 419, 1989.
20. Crawford, E. D., Blumenstein, B. A. and Goodman, P. J.: Leuprolide with and without flutamide in advanced prostate cancer. Cancer, 66: 1039, 1990.
21. Connolly, J. A., Shinohara, K. and Presti, J. C., Jr.: Local recurrence after radical prostatectomy: characteristics in size, location and relationship to prostate specific antigen and surgical margins. Urology, 47: 225, 1996.